The earliest pathologic alterations in dysferlinopathy

被引:120
|
作者
Selcen, D
Stilling, G
Engel, AG
机构
[1] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA
[2] Mayo Clin, Neuromuscular Res Lab, Rochester, MN 55905 USA
关键词
D O I
10.1212/WNL.56.11.1472
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Dysferlinopathies are associated with proximal or distal muscular dystrophy. Dysferlin immunolocalizes to the muscle fiber periphery but does not associate with the dystrophin-glycoprotein complex; its function in humans, and the mechanism by which it causes muscle fiber injury, are not known. The authors therefore searched for pathogenetic clues by examining early abnormalities in nonnecrotic muscle fibers in dysferlinopathy. Five dysferlin-deficient patients were investigated. Weakness was distal in two, proximal in one, and both proximal and distal in two. Patient 5 was only mildly affected. Methods: Immunoblot analysis, membrane attack complex (MAC) immunolocalization, and quantitative electron microscopy. Results: In Patients 1 through 4, but not in 5, part or the entire surface of isolated nonnecrotic muscle fibers immunostained for MAC. Quantitative electron microscopy of 175 nonnecrotic muscle fibers revealed one or more of the following: 1) small (0.11 to 1.8 mum) plasmalemmal defects in 64% of fibers; 2) thickened basal lamina over some defects; 3) replacement of the plasma membrane by one to multiple layers of small vesicles in 57% of fibers; 4) papillary projections, frequently disintegrating, in 24 to 36% of fibers in Patients 1 through 4 but absent in fibers of Patient 5; 5) small subsarcolemmal vacuoles, some undergoing exocytosis, in 57% of fibers; and 6) infrequent subsarcolemmal regions containing rough endoplasmic reticulum and abundant fi ee ribosomes. Conclusions: Dysferlin is likely required for maintaining the structural integrity of the muscle fiber plasma membrane, and plasma membrane injury is an early event in the pathogenesis of dysferlinopathy. MAC activation can participate in but is not an initial or primary event causing muscle fiber injury.
引用
收藏
页码:1472 / 1481
页数:10
相关论文
共 50 条
  • [31] Phenotypic Variation in Dysferlinopathy
    Celik, Munevver
    Ertasoglu, Hulya
    JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, 2009, 26 (01): : 106 - 111
  • [32] Respiratory dysfunction of dysferlinopathy
    Nishikawa, A.
    Mori-Yoshimura, M.
    Hayashi, Y.
    Oya, Y.
    Nishino, I.
    Murata, M.
    NEUROMUSCULAR DISORDERS, 2012, 22 (9-10) : 895 - 895
  • [33] Dysferlinopathy in two siblings
    Brabeck, C
    Neu, I
    Kress, W
    Bornemann, A
    ACTA NEUROPATHOLOGICA, 2001, 102 (05) : 520 - 520
  • [34] Dysferlinopathy: a new myopathy
    Serratrice, G
    Pellissier, JF
    N'Guyen, V
    Attarian, S
    Pouget, J
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2002, 186 (06): : 1025 - 1034
  • [35] Conformational change as one of the earliest alterations of tan in Alzheimer's disease
    Weaver, CL
    Espinoza, M
    Kress, Y
    Davies, P
    NEUROBIOLOGY OF AGING, 2000, 21 (05) : 719 - 727
  • [36] EARLIEST ALTERATIONS IN RAT NEURONS AND ASTROCYTES AFTER ANOXIA-ISCHEMIA
    BROWN, AW
    BRIERLEY, JB
    ACTA NEUROPATHOLOGICA, 1973, 23 (01) : 9 - 22
  • [37] FURTHER EVIDENCE THAT ONE OF THE EARLIEST ALTERATIONS IN COLORECTAL CARCINOGENESIS INVOLVES APC
    TSAO, JI
    SHIBATA, D
    AMERICAN JOURNAL OF PATHOLOGY, 1994, 145 (03): : 531 - 534
  • [38] Clinical heterogeneity in dysferlinopathy
    Ueyama, H
    Kumamoto, T
    Horinouchi, H
    Fujimoto, S
    Aono, H
    Tsuda, T
    INTERNAL MEDICINE, 2002, 41 (07) : 532 - 536
  • [39] North Star Assessment for dysferlinopathy: Longitudinal performance in the clinical outcome study of dysferlinopathy
    James, M.
    Mayhew, A.
    Eagle, M.
    Lofra, R. Muni
    Maron, E.
    Gee, R.
    Harman, M.
    Duong, T.
    Vandevelde, B.
    Siener, C.
    Thiele, S.
    Mendez, J.
    Canal, A.
    Sakamoto, C.
    Holsten, S.
    Pedrosa-Hernandez, I.
    Semplicini, C.
    Lowes, L.
    Bushby, K.
    Straub, V.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S145 - S145
  • [40] Clinical Outcome Study of Dysferlinopathy: what are the best outcome measures for dysferlinopathy patients?
    James, M. K.
    Jacobs, M.
    Mayhew, A.
    Feng, J.
    Spuler, S.
    Day, J. W.
    Jones, K. J.
    Bharucha-Goebel, D. X.
    Salort-Campana, E.
    Pestronk, A.
    Walter, M. C.
    Paradas, C.
    Stojkovic, T.
    Mori-Yoshimura, M.
    Bravver, E.
    Manera, J. Diaz
    Pegoraro, E.
    Mendell, J. R.
    Bushby, K.
    Straub, V.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S6 - S6